Balsalazide (disodium)

Balsalazide disodium is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].

Product Specifications

CAS Number

[213594-60-6]

UNSPSC

12352005

Target

Interleukin Related; STAT

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C(C1=CC(/N=N/C2=CC=C(C(NCCC(O[Na])=O)=O)C=C2)=CC=C1O)O[Na]

Molecular Formula

C17H13N3Na2O6

Molecular Weight

401.28

References & Citations

[1]Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31 (8) :1453-61.|[2]Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49 (6) : p. 783-789.|[3]Seema A Patil, et al. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008 Apr;2 (2) :177-84.